Oral Abstract | Pharmacokinetics studies for better treatment of TB

Thursday, November 16, 2:30am - 4:00am (EST)

Time shown in-05:00 America, New York

This Oral Abstract presentation will review results from the Phase 1 research into TBAJ-876, a new anti-TB compound being developed by TB Alliance. Abstract presentations will include "Antimycobacterial activity of a novel diarylquinoline (TBAJ-876) against diverse drug-susceptible and drug-resistant clinical isolates of M. tuberculosis."

Please see the online program for more information.

Add to Calendar 2023/11/16 08:30:00 2023/11/16 10:00:00 Europe/Paris Oral Abstract | Pharmacokinetics studies for better treatment of TB This Oral Abstract presentation will review results from the Phase 1 research into TBAJ-876, a new anti-TB compound being developed by TB Alliance. Abstract presentations will include "Antimycobacterial activity of a novel diarylquinoline (TBAJ-876) against diverse drug-susceptible and drug-resistant clinical isolates of M. tuberculosis."

Please see the online program for more information.

242A false MM/DD/YYYY 30 OPAQUE ambQfBYOGzRZxDTimmgh72967

242A

TB Alliance at the Union Conference

Link: